医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PharmaEngine Announces Merrimack Completed MM-398 (PEP02) New Drug Application Submission to U.S. FDA

2015年04月28日 AM10:00
このエントリーをはてなブックマークに追加


 

TAIPEI, Taiwan

PharmaEngine, Inc. (TWO:4162) today announced that its licensing partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection) to the U.S. Food and Drug Administration (FDA) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Merrimack also announced that they have requested priority review of the MM-398 NDA by the FDA.

MM-398 NDA application is supported by the data from a Phase 3 study (NAPOLI-1) conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. MM-398 in combination with 5-fluorouracil (5-FU) and leucovorin achieved its primary and secondary endpoints by demonstrating a statistically significant improvement in overall survival, progression free survival, and overall response rate compared to the control arm of 5-FU and leucovorin alone. This was the first global Phase 3 study in a post-gemcitabine setting to show a survival benefit in this devastating disease. The topline and expanded analysis data were presented in June 2014 and January 2015.

“Drug development is similar to a relay race; PharmaEngine developed MM-398 (also known as PEP02) from preclinical to phase 2 clinical stages, and passed the baton to Merrimack who accelerated its development through a successful global phase 3 trial,” said C. Grace Yeh, Ph.D., President and CEO of PharmaEngine. “We are pleased to have collaborated with Merrimack in the NAPOLI-1 study and the US NDA filing process. We will use the data package from the US NDA filing to form the basis of our Taiwan NDA submission.”

“The submission of Merrimack’s first ever NDA with the U.S. FDA is a major milestone in the company’s history and a significant step forward in our commitment to delivering new treatment options to cancer patients,” said Robert Mulroy, President and CEO at Merrimack. “We are grateful for the work PharmaEngine did to bring MM-398 to Phase 3 and look forward to working with them as they prepare for their submission in Taiwan.”

In accordance with the First Amendment to the License and Collaboration Agreement signed by PharmaEngine and Merrimack in September 2014, Merrimack is contractually obligated to pay PharmaEngine a milestone of US$5 million by April 30, 2015.

About MM-398 (PEP02)

MM-398 (PEP02, irinotecan liposome injection) is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. In May 2011, PharmaEngine and Merrimack executed an exclusive license agreement. Under the terms of the agreement, PharmaEngine granted back Merrimack the rights to develop, manufacture, and commercialize PEP02 (designated as MM-398 by Merrimack) in Asia and Europe, and retained the same rights in Taiwan. In September 2014, Merrimack licensed the rights to MM-398 outside of the US and Taiwan to Baxter International’s biopharmaceutical business (Baxter, NYSE:BAX). In 2011, MM-398 received orphan drug designation from both the US FDA and European Medicines Agency (EMA) for the treatment of pancreatic cancer. In addition, MM-398 received Fast Track Designation for post-gemcitabine metastatic pancreatic cancer from the US FDA in November 2014.

About PharmaEngine, Inc. (TWO: 4162)

PharmaEngine is a biopharmaceutical company established in Taipei, Taiwan. PharmaEngine focuses on the development of new medications for the treatment of cancer and Asian prevalent diseases. PharmaEngine has three projects: PEP02 (MM-398) in pre-NDA stage; PEP503 (NBTXR3) in a global pivotal trial of soft tissue sarcoma; and PEP06 in drug discovery. For further information, please visit PharmaEngine’s website at http://www.pharmaengine.com.

CONTACT

PharmaEngine, Inc.
Peter Wu, +886-2-2515-8228, ext. 500
Mobile:
+886-935-154-559
Director, Corporate Development
peter.wu@pharmaengine.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田在美国临床肿瘤学会(ASCO)和欧洲血液学会(EHA)年会上重点介绍其强大的肿瘤产品阵容和后续产品线数据
  • AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model
  • GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing
  • GRAIL(思为诺)宣布完成3亿美元C轮融资获超额认购
  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明